Sulfated Polysaccharide 3-O-Sulfation Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing non-animal-derived heparin analogs with anticoagulant activity face challenges in replicating the sulfation pattern and potency of animal-derived heparin, with existing alternatives either having side reactions or reduced anticoagulant strength.
Innovation Solution
A novel sulfated polysaccharide with a repetitive structure of hexuronic acid and α-D-glucosamine residues, exhibiting high 3-O-sulfation rates and anticoagulant activity, is developed, comprising a specific disaccharide unit with defined sulfate group ratios and molecular weight range, achieved through enzymatic and chemical modifications of heparosan.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If chemical conversion method is used to produce heparin-analogous polysaccharides, then 3-O-sulfation rate in glucosamine residues is high, but 3-O-sulfation of glucuronic acid residues occurs causing side reactions
Solution Approach 1:
The patent uses enzymatic conversion as an intermediary method between chemical conversion and direct animal-derived heparin. Specific sulfotransferase enzymes are employed to catalyze the sulfation reaction, providing selective 3-O-sulfation of glucosamine residues without the non-selective side reactions of chemical methods. The enzyme acts as a mediator that achieves high manufacturing precision while avoiding harmful side reactions.
Solution Approach 2:
The patent changes the reaction parameters by using enzymatic catalysis instead of chemical reagents. By controlling enzyme specificity, temperature, pH, and substrate concentration, the sulfation reaction achieves high selectivity for glucosamine residues at the 3-O position, maintaining a sulfation rate of 80% or more while preventing sulfation of glucuronic acid residues that would cause side reactions.
2Manufacturing precision
If enzymatic conversion method is used to produce heparin-analogous polysaccharides, then sulfation pattern matches animal-derived heparin, but anticoagulant activity is reduced to about half
Solution Approach 1:
The patent applies local quality by achieving high 3-O-sulfation specifically at the C-3 position of glucosamine residues (80% or more sulfation rate) while maintaining other structural features. This localized high-density sulfation at the critical anticoagulant site enhances binding affinity to antithrombin III, thereby improving anticoagulant activity while maintaining the natural sulfation pattern observed in animal-derived heparin.
Solution Approach 2:
The patent creates a composite structure by combining multiple sulfation patterns (N-sulfation, 2-O-sulfation, and high 3-O-sulfation) in a specific arrangement that mimics and enhances the natural heparin structure. This composite sulfation pattern achieves both high manufacturing precision matching animal-derived heparin and high reliability in terms of anticoagulant activity, overcoming the limitation of previous enzymatic methods that produced only half the expected activity.
3Object-affected harmful factors
If non-animal-derived heparin is developed, then contamination risk is eliminated, but structural characteristics and anticoagulant strength differ from animal-derived heparin
Solution Approach 1:
The patent uses copying by replicating the precise sulfation pattern of animal-derived heparin through enzymatic conversion of heparosan. The sulfotransferase enzymes copy the natural sulfation positions and densities, achieving a structural characteristics match with animal-derived heparin while using microbially produced heparosan as the starting material, thus eliminating contamination risk from animal sources.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel sulfated polysaccharide demonstrates enhanced anticoagulant activity, specifically inhibiting factor Xa and factor IIa with a high activity ratio, while minimizing side reactions, thus offering a potent and controlled anticoagulant alternative to traditional heparin.
Implementation Method 1
a method mainly involving enzymatic conversion have been reported
Implementation Method 2
Antithrombin III inhibits thrombin, factor Xa (active form of a factor X) and other serine proteases by binding to its active serine site
Data Source
AI summary
The present invention provides a novel sulfated polysaccharide having an anticoagulant activity. Specifically, the present invention provides the polysaccharide comprising a repetitive structure of a disaccharide unit composed of a hexuronic acid (HexA) residue and a α-D-glucosamine (GlcN) residue and having 13% or higher of a 3-O-sulfation rate in GlcN residues.